Invitrogen™ Pregnanediol-3-Glucuronide (PDG) Competitive ELISA Kit

Description

The Pregnanediol-3-Glucuronide (PDG) ELISA quantitates PDG in extracted serμm/plasma, urine, dried fecal extracts or cell culture medium. The assay will exclusively recognize both natural and recombinant PDG. Principle of the method The PDG solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, binding to the target on a different epitope from the capture antibody. A conjugated enzyme has been incorporated into the assay. After incubation and washing steps to rid the microplate of unbound substances, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is inversely proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

Pregnanediol-3-Glucuronide (PDG) is a natural human metabolite of Pregnanediol generated in the liver by UDP glucuonyltransferase. Glucuronidation is used to assist in the excretion of toxic substances, drugs or other substances that cannot be used as an energy source. Glucuronic acid is attached via a glycosidic bond to the substance, and the resulting glucuronide, which has much higher water solubility than the original substance, is eventually excreted by the kidneys.